Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 3, 28 April 2023
Open
Access | Article
New Treatment of Alzheimer’s Disease
* Author to whom correspondence should be addressed.
Abstract
Alzheimer’s disease is a major degenerative disease characterized by impaired memory, aphasia, apraxia and the changes of personality and behavior. As the population ages, the incidence of AD is increasing. According to an analysis of 10000 people with up to 30 years of follow-up data, elderly over 55 years old, the risk of dementia increased nearly four- fold if they have three or more chronic diseases at the age of 55. The pathogenesis of AD has not been fully studied, a lot of mechanisms such as neuroinflammation, mitochondrial dysfunction, abnormal metabolic are related to the pathology of AD. The abnormal deposition of Aβ and hyperphosphorylation of Tau protein are identified mechanism of AD. Finding new drugs for AD has always been a research hotpot, preclinical work of new anti-AD drugs is being carried out on a large scale in the world. However, in all types of new developing drugs for AD, the failure rate is about 99%. The drugs approved to treat AD such as acetylcholinesterase inhibitors and glutamate receptor antagonists, only slow symptoms other than change the progression of this disease. Deep researches are required to study the pathogenesis of AD, developing drugs that can reverse the progression is the key to the treatment for AD. This review introduces new developing therapy and potential targets of future research into treatments of AD.
Keywords
Alzheimer’s disease, new developing drugs, pathogenesis
References
1. S. Mazzucchi, G. Palermo, N. Campese, et al.The role of synaptic biomarkers in the spectrum of neurodegenerative diseases[J].Expert Review of Proteomics，2020，17：543-559.
2. J. Jia, C. Wei, L. Jia, et al.Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial[J].Journal of Alzheimer's Disease : JAD，2017，56(4)：1495-1504.
3. A. Martorell, A. Paulson, H. Suk, et al.Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition[J].Cell，2019，177(2)：256-271.e22.
4. A. Cimenser, E. Hempel, T. Travers, et al.Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer's Disease Patients[J].Frontiers in Systems Neuroscience，2021，15：746859.
5. D. Yu, H. Yan, J. Zhou, et al.A circuit view of deep brain stimulation in Alzheimer's disease and the possible mechanisms[J].Molecular Neurodegeneration，2019，14(1)：33.
6. R. Shapira, A. Gdalyahu, I. Gottfried, et al.Hyperbaric oxygen therapy alleviates vascular dysfunction and amyloid burden in an Alzheimer's disease mouse model and in elderly patients[J].Aging，2021，13(17)：20935-20961.
7. M. Brody, M. Agronin, B. Herskowitz, et al.Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease[J].Alzheimer's & Dementia : the Journal of the Alzheimer's Association，2022，
8. M. Boada, O. López, J. Olazarán, et al.Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study[J].Alzheimer's & Dementia : the Journal of the Alzheimer's Association，2021，
9. Y. Shao and T. Xu.A study on the neuroprotective effect of miR-206-3p on Alzheimer's disease mice by regulating brain-derived neurotrophic factor[J].Annals of Translational Medicine，2022，10(2)：85.
10. T. Sun, K. Zhao, M. Liu, et al.miR-30a-5p induces Aβ production via inhibiting the nonamyloidogenic pathway in Alzheimer's disease[J].Pharmacological Research，2022，178：106153.
11. T. Pohlkamp, X. Xian, C. Wong, et al.NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load[J].eLife，2021，10
12. J. Rosenberg, M. Kaplitt, B. De, et al.AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease[J].Human gene therapy. Clinical Development，2018，29(1)：24-47.
13. C. Nørgaard, S. Friedrich, C. Hansen, et al.Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers[J]. Alzheimer's & Dementia (New York, N. Y.)，2022，8(1)：e12268.
14. J. Zheng, Y. Xie, L. Ren, et al.GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease[J].Molecular Metabolism，2021，47：101180.
15. X. Cen, Y. Chen, X. Xu, et al.Pharmacological targeting of MCL-1 promotes mitophagy and improves disease pathologies in an Alzheimer's disease mouse model[J].Nature Communications，2020，11(1)：5731.
16. T. Wang, W. Kuang, W. Chen, et al.A phase II randomized trial of sodium oligomannate in Alzheimer's dementia[J].Alzheimer's Research & Therapy，2020，12(1)：110.
17. S. Xiao, P. Chan, T. Wang, et al.A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia[J].Alzheimer's Research & Therapy，2021，13(1)：62.
18. M. Mintun, A. Lo, C. Duggan Evans, et al.Donanemab in Early Alzheimer's Disease[J].The New England Journal of Medicine，2021，384(18)：1691-1704.
19. S. Doggrell.Still grasping at straws: donanemab in Alzheimer's disease[J].Expert Opinion on Investigational Drugs，2021，30(8)：797-801.
20. C. Swanson, Y. Zhang, S. Dhadda, et al.A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody[J].Alzheimer's Research & Therapy，2021，13(1)：80.
21. G. Alexander, S. Emerson and A. Kesselheim.Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility[J].JAMA，2021，325(17)：1717-1718.
22. E. Vijverberg, T. Axelsen, A. Bihlet, et al.Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD[J].Alzheimer's Research & Therapy，2021，13(1)：142.
23. T. Hoffmann, J. Rahfeld, M. Schenk, et al.Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice[J].International Journal of Molecular Sciences，2021，22(21)
24. W. Wang, Q. Zhou, T. Jiang, et al.A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models[J].Theranostics，2021，11(11)：5279-5295.
25. M. Vaz and S. Silvestre.Alzheimer's disease: Recent treatment strategies[J].European Journal of Pharmacology，2020，887：173554.
26. M. Alavi, S. Fanoudi, M. Hosseini and H. Sadeghnia.Beneficial effects of levetiracetam in streptozotocin-induced rat model of Alzheimer's disease[J].Metabolic Brain Disease，2022，37(3)：689-700.
27. K. Vossel, K. Ranasinghe, A. Beagle, et al.Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial[J].JAMA neurology，2021，78(11)：1345-1354.
28. C. Singh, K. Choi, L. Munro, et al.Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics[J].EBioMedicine，2021，71：103503.
29. O. Sanders.Sildenafil for the Treatment of Alzheimer's Disease: A Systematic Review[J].Journal of Alzheimer's Disease Reports，2020，4(1)：91-106.
30. W. Zhang, M. Lv, Y. Shi, et al.Network Pharmacology-Based Study of the Underlying Mechanisms of Huangqi Sijunzi Decoction for Alzheimer's Disease[J].Evidence-based Complementary and Alternative Medicine : eCAM，2021，2021：6480381.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part I
- ISBN (Print)
- 978-1-915371-25-6
- ISBN (Online)
- 978-1-915371-26-3
- Published Date
- 28 April 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/3/20220172
- Copyright
- 28 April 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited